SciVision Biotech Inc., founded in 2001, is now a public company listed at Taiwan Stock Exchang (Stock symbol : 1786) SciVision Biotech Inc. manufactures Hyaluronic acid products by using own-developed Cross-linked Hyaluronic Acid Platform (CHAP) to make the characteristics of Hyaluronic acid products be precisely controllable, and can be widely used in the production of cross-
linked Hyaluronic acid products with different types and physical properties. The technology of Cross-linked Hyaluronic Acid Platform (CHAP) established the leading position of SciVision Biotech Inc. in the field of medical grade Hyaluronic acid products.
The population structures of both developed and developing countries are gradually moving towards an aging society. The pursuit of beauty and health, as well as the demand for medical care of degenerative diseases has increased day by day. The main products of our company are Hyaluronic acid dermal fillers (for medical and cosmetic surgical use), Hyaluronic acid anti-adhesion gels (for surgical use) and Hyaluronic acid viscosupplement (for treatment of knee osteoarthritis). The three Hyaluronic acid products are high-
level medical devices that cater to the commercial possibilities for next 10-year growth. Today, our company has gradually increased the technology scale and is being devoted to the health and beauty fields, to create a better vision and reach the human’s aesthetic realm
SciVision Biotech acquired a nearly 20,000 square meter site located in Kaohsiung Cianjhen Technology Industrial Park for the construction of a new manufacturing facility to accommodate the growing production needs. The facility was GMP certified, and was constructed based on FDA standard, fully equipped with advanced automatic equipment.
We work with pharmaceutical and specialty companies worldwide to develop long-term competitiveness. SciVision’s vision is to contribute its accumulated technologies and experience for the benefit of all humankind, to develop high-quality, high-efficiency products, to improve the health and the quality of life of the public, and to become a leading company in Taiwan’s biotech industry, while continue our growth in the global market